Developer docs
API playgroundTry for free, no card

Search company profiles

Proinnovera

Full company profile

uuid000m8cp

Namestring
Proinnovera
Legal namestring
Symbio Research
Websiteurl
proinnovera.com
Company typeenum
Private
Founded yearint
1997
Descriptiontext

Proinnovera is a German-based Contract Research Organization (CRO), headquartered in Münster, providing clinical research and consulting services to pharmaceutical and biotechnology clients. Founded in 1997 and operating with 51-100 employees, the firm specializes in clinical development across four therapeutic areas: dermatology, aesthetics, gastroenterology, and inflammation, with particular expertise in topical formulation development for dermatological and aesthetic applications. The business operates on a professional services model, executing clinical trials and delivering research services under negotiated B2B contracts with pharma and biotech companies on a project-by-project basis.

In October 2023, Proinnovera merged with Symbio and the Dow Group to form a unified entity initially branded Symbio Proinnovera. Following the integration, the combined organization rebranded to Symbio in September 2024, retaining the Dow Development Laboratory branding as a wholly-owned subsidiary. The current company claims a Global geographic reach and positions itself as a specialized mid-sized Global CRO differentiated by combined therapeutic expertise and topical formulation capabilities. CEO Alan Morgan leads the organization, which has migrated its email communications to the symbioresearch.com domain. Distribution relies on direct enterprise client engagement rather than traditional sales channels, with marketing presence across LinkedIn, X, and Facebook supplementing the firm's website and client communications.

The company has no disclosed funding rounds, no public revenue figures, and no parent company or private equity backing indicated in available data. The Dow Development Laboratory subsidiary is the only disclosed corporate structure element, retained as an acquired brand following the merger integration.

Short descriptiontext

Proinnovera is a German-based Global CRO providing clinical research and topical formulation development services to pharmaceutical and biotech clients across dermatology, aesthetics, gastroenterology, and inflammation therapeutic areas.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersMuenster, Germany
HQ citystring
Muenster
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
contract research services, clinical trial management, topical formulation development, pharmaceutical consulting, therapeutic area research
Industry2 codes
PRIMARYHLAGAAAL
Specialty Therapeutic-Area CROs (e.g., oncology/rare disease)
SECONDARYHLAGAAAA
Clinical CROs (Phase I–IV)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
Product category
Contract Research Organization (CRO) Services
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Contract Research Services
TypeProfessional Services
Description

Professional services revenue generated through conducting clinical trials and providing research services to pharmaceutical and biotech companies under contract arrangements.

symbioresearch.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Operations, Technology or R&D, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Proinnovera, now operating as part of Symbio following the 2023 merger with Symbio & Dow Group, is a Global Contract Research Organization (CRO) that provides consulting, planning, and implementation services for pharmaceutical product development. The company delivers clinical research services with specialized topical formulation development capabilities and focused therapeutic area expertise in dermatology, aesthetics, gastroenterology, and inflammation for pharmaceutical and biotech clients.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Symbio (formerly Symbio Proinnovera) is a Global Contract Research Organization (CRO) providing clinical research services. The company offers a unified portfolio combining topical formulation development services with therapeutic expertise across four key areas: Dermatology, Aesthetics, Gastroenterology, and Inflammation. Services include specialized topical formulation development and access to Symbio's global research networks, all delivered as an integrated CRO offering to pharmaceutical and biotech clients.

Product and service6 records
1Topical Formulation Development
CategoryFormulation Development Services
Description

Specialized development services for topical pharmaceutical formulations, supporting drug development in dermatology and aesthetics therapeutic areas. Targeted at pharmaceutical and biotech companies requiring topical drug product development expertise.

2Symbio's Networks
CategoryClinical Trial Network Services
Description

Global network services connecting pharmaceutical and biotech clients with clinical trial capabilities and research infrastructure across multiple regions worldwide. Provides access to international research sites and trial execution resources.

3Dermatology Clinical Research
CategoryTherapeutic Area Clinical Research
Description

Clinical research services for dermatological conditions and treatments, supporting pharmaceutical and biotech clients developing drugs for skin-related indications.

4Aesthetics Clinical Research
CategoryTherapeutic Area Clinical Research
Description

Clinical research and development services for aesthetic medicine products, serving pharmaceutical and biotech clients developing aesthetic and cosmetic pharmaceutical products.

5Gastroenterology Clinical Research
CategoryTherapeutic Area Clinical Research
Description

Clinical research services for gastrointestinal conditions and treatments, supporting pharmaceutical and biotech clients developing drugs for GI-related indications.

6Inflammation Clinical Research
CategoryTherapeutic Area Clinical Research
Description

Clinical research and drug development services for inflammation-related conditions, serving pharmaceutical and biotech clients developing anti-inflammatory therapeutics.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-09-01
Description

Dow Group merged with Symbio and Proinnovera GmbH to form the unified Symbio organization. The Dow Development Laboratory branding remains unchanged as part of the post-merger integration. This merger combined the expertise and capabilities of three organizations into a single Global CRO entity.

2Proinnovera GmbH
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-01-01
Description

Proinnovera GmbH merged with Symbio and Dow Group. The combined entity operated under the name Symbio Proinnovera before rebranding to simply Symbio in September 2024. The merger brought together complementary expertise in clinical research services.

symbioresearch.com
Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global full-service CRO spin-out from Labcorp; competes across the same therapeutic areas and customer base that Symbio targets.

TypeDirect peer
Description

Mid-size, therapeutically-focused CRO with strong specialty-area expertise — the most directly comparable publicly-listed specialty CRO business model to Symbio's TA-driven positioning.

TypeDirect peer
Description

Mid-size CRO with concentrated therapeutic-area expertise in similar specialty categories; competes for the same kind of specialty biotech and mid-pharma clinical development work.

TypeDirect peer
Description

Smaller private CRO with a therapeutic-area-focused model, comparable in size and operating posture to Symbio's specialty mid-tier positioning.

TypeBroad incumbent
Description

Global full-service CRO covering all major therapeutic areas; sets the benchmark Symbio competes against when sponsors consolidate spend with a single large provider.

TypeBroad incumbent
Description

One of the largest global CROs offering full-service clinical development across all therapeutic areas — represents the incumbent scale competitor for any CRO growing into broader mandates.

TypeBroad incumbent
Description

World's largest CRO with global infrastructure, technology platforms, and analytics — the dominant broad incumbent that mid-tier specialty CROs like Symbio compete against for sponsor share.

TypeBroad incumbent
Description

Large CRO/CDMO with significant clinical services business; broad incumbent playing in dermatology and inflammation — directly relevant therapeutic-area overlap with Symbio.

TypeBroad incumbent
Description

Large biopharma solutions and clinical development services provider; competes for outsourced clinical work from the same pharma/biotech customer base Symbio serves.

TypeEmerging player
Description

Mid-size CRO/CDMO with growing clinical and bioanalytical services; emerging specialty player of comparable scale whose expansion in dermatology-related work is a relevant adjacency to Symbio.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment6 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Proinnovera

Contract Research Organization (CRO) Servicesproinnovera.com

Proinnovera is a German-based Global CRO providing clinical research and topical formulation development services to pharmaceutical and biotech clients across dermatology, aesthetics, gastroenterology, and inflammation therapeutic areas.

What Proinnovera does

Proinnovera is a German-based Contract Research Organization (CRO), headquartered in Münster, providing clinical research and consulting services to pharmaceutical and biotechnology clients. Founded in 1997 and operating with 51-100 employees, the firm specializes in clinical development across four therapeutic areas: dermatology, aesthetics, gastroenterology, and inflammation, with particular expertise in topical formulation development for dermatological and aesthetic applications. The business operates on a professional services model, executing clinical trials and delivering research services under negotiated B2B contracts with pharma and biotech companies on a project-by-project basis.

In October 2023, Proinnovera merged with Symbio and the Dow Group to form a unified entity initially branded Symbio Proinnovera. Following the integration, the combined organization rebranded to Symbio in September 2024, retaining the Dow Development Laboratory branding as a wholly-owned subsidiary. The current company claims a Global geographic reach and positions itself as a specialized mid-sized Global CRO differentiated by combined therapeutic expertise and topical formulation capabilities. CEO Alan Morgan leads the organization, which has migrated its email communications to the symbioresearch.com domain. Distribution relies on direct enterprise client engagement rather than traditional sales channels, with marketing presence across LinkedIn, X, and Facebook supplementing the firm's website and client communications.

The company has no disclosed funding rounds, no public revenue figures, and no parent company or private equity backing indicated in available data. The Dow Development Laboratory subsidiary is the only disclosed corporate structure element, retained as an acquired brand following the merger integration.

Proinnovera firmographics

Firmographics
Name
Proinnovera
Legal name
Symbio Research
Website
https://proinnovera.com
Company type
Private
Founded year
1997
Operating status
Operating
Headcount range
51–100 employees
Short description
Proinnovera is a German-based Global CRO providing clinical research and topical formulation development services to pharmaceutical and biotech clients across dermatology, aesthetics, gastroenterology, and inflammation therapeutic areas.
Ownership category
akta.pro rank

Proinnovera industry classification

Industry
Product category
Contract Research Organization (CRO) Services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
akta.pro industry
PRIMARYHLAGAAAL
Specialty Therapeutic-Area CROs (e.g., oncology/rare disease)
SECONDARYHLAGAAAA
Clinical CROs (Phase I–IV)

Keywords

  • Contract research services
  • Clinical trial management
  • Topical formulation development
  • Pharmaceutical consulting
  • Therapeutic area research

Where Proinnovera is headquartered

Location

Headquarters

HQ city
Muenster
HQ country
Germany
HQ region
Europe

Markets served

Proinnovera business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales

Revenue model

  1. Contract Research Services: Professional services revenue generated through conducting clinical trials and providing research services to pharmaceutical and biotech companies under contract arrangements.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Proinnovera product offering

Product offering

Core offering

Proinnovera, now operating as part of Symbio following the 2023 merger with Symbio & Dow Group, is a Global Contract Research Organization (CRO) that provides consulting, planning, and implementation services for pharmaceutical product development. The company delivers clinical research services with specialized topical formulation development capabilities and focused therapeutic area expertise in dermatology, aesthetics, gastroenterology, and inflammation for pharmaceutical and biotech clients.

Product overview

Symbio (formerly Symbio Proinnovera) is a Global Contract Research Organization (CRO) providing clinical research services. The company offers a unified portfolio combining topical formulation development services with therapeutic expertise across four key areas: Dermatology, Aesthetics, Gastroenterology, and Inflammation. Services include specialized topical formulation development and access to Symbio's global research networks, all delivered as an integrated CRO offering to pharmaceutical and biotech clients.

Differentiator

Problem solved

Functional benefit

Products and services

  • Topical Formulation Development Specialized development services for topical pharmaceutical formulations, supporting drug development in dermatology and aesthetics therapeutic areas. Targeted at pharmaceutical and biotech companies requiring topical drug product development expertise.
  • Symbio's Networks Global network services connecting pharmaceutical and biotech clients with clinical trial capabilities and research infrastructure across multiple regions worldwide. Provides access to international research sites and trial execution resources.
  • Dermatology Clinical Research Clinical research services for dermatological conditions and treatments, supporting pharmaceutical and biotech clients developing drugs for skin-related indications.
  • Aesthetics Clinical Research Clinical research and development services for aesthetic medicine products, serving pharmaceutical and biotech clients developing aesthetic and cosmetic pharmaceutical products.
  • Gastroenterology Clinical Research Clinical research services for gastrointestinal conditions and treatments, supporting pharmaceutical and biotech clients developing drugs for GI-related indications.
  • Inflammation Clinical Research Clinical research and drug development services for inflammation-related conditions, serving pharmaceutical and biotech clients developing anti-inflammatory therapeutics.

Companies that use Proinnovera

Customer profile

Segments6 records

Ideal customer profiles1 record

Proinnovera technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Proinnovera partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Dow GroupcoreStrategic or Co-development Partner · 1 September 2024Dow Group merged with Symbio and Proinnovera GmbH to form the unified Symbio organization. The Dow Development Laboratory branding remains unchanged as part of the post-merger integration. This merger combined the expertise and capabilities of three organizations into a single Global CRO entity.
  • Proinnovera GmbHcoreStrategic or Co-development Partner · 1 January 2023Proinnovera GmbH merged with Symbio and Dow Group. The combined entity operated under the name Symbio Proinnovera before rebranding to simply Symbio in September 2024. The merger brought together complementary expertise in clinical research services.

Scale indicators1 record

Recent moves5 records

Expansion highlights3 records

Proinnovera competitors and assessment

Company assessment

Broad incumbents

  • Fortrea (formerly Labcorp Drug Development): Global full-service CRO spin-out from Labcorp; competes across the same therapeutic areas and customer base that Symbio targets.
  • Parexel International: Global full-service CRO covering all major therapeutic areas; sets the benchmark Symbio competes against when sponsors consolidate spend with a single large provider.
  • ICON plc: One of the largest global CROs offering full-service clinical development across all therapeutic areas — represents the incumbent scale competitor for any CRO growing into broader mandates.
  • IQVIA: World's largest CRO with global infrastructure, technology platforms, and analytics — the dominant broad incumbent that mid-tier specialty CROs like Symbio compete against for sponsor share.
  • Charles River Laboratories: Large CRO/CDMO with significant clinical services business; broad incumbent playing in dermatology and inflammation — directly relevant therapeutic-area overlap with Symbio.
  • Syneos Health: Large biopharma solutions and clinical development services provider; competes for outsourced clinical work from the same pharma/biotech customer base Symbio serves.

Direct peers

  • Medpace: Mid-size, therapeutically-focused CRO with strong specialty-area expertise — the most directly comparable publicly-listed specialty CRO business model to Symbio's TA-driven positioning.
  • Worldwide Clinical Trials: Mid-size CRO with concentrated therapeutic-area expertise in similar specialty categories; competes for the same kind of specialty biotech and mid-pharma clinical development work.
  • Clinipace Worldwide: Smaller private CRO with a therapeutic-area-focused model, comparable in size and operating posture to Symbio's specialty mid-tier positioning.

Emerging players

  • Frontage Laboratories: Mid-size CRO/CDMO with growing clinical and bioanalytical services; emerging specialty player of comparable scale whose expansion in dermatology-related work is a relevant adjacency to Symbio.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat2 records

Key risks6 records

Key highlights6 records

Customer concentration

Proinnovera social profiles

Digital presence

Proinnovera financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Proinnovera leadership team

Management profile

Number of profiles

Profiles1 record

Proinnovera subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Proinnovera funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Proinnovera M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Proinnovera

What does Proinnovera do?

Proinnovera, now operating as part of Symbio following the 2023 merger with Symbio & Dow Group, is a Global Contract Research Organization (CRO) that provides consulting, planning, and implementation services for pharmaceutical product development. The company delivers clinical research services with specialized topical formulation development capabilities and focused therapeutic area expertise in dermatology, aesthetics, gastroenterology, and inflammation for pharmaceutical and biotech clients.

Is Proinnovera a public or private company?

Proinnovera is a private company. It is classified as unknown and is currently operating.

When was Proinnovera founded?

Proinnovera was founded in 1997. It employs 51 to 100 people.

Where is Proinnovera based?

Proinnovera is headquartered in Muenster, Germany, in the Europe region.

How does Proinnovera make money?

One revenue line is on record: contract Research Services.

Who are Proinnovera's main competitors?

Broad incumbents on record are Fortrea (formerly Labcorp Drug Development), Parexel International, ICON plc, IQVIA, Charles River Laboratories and Syneos Health. Direct peers are Medpace, Worldwide Clinical Trials and Clinipace Worldwide. Frontage Laboratories is listed as an emerging player.

Does Proinnovera have an API?

No public API is recorded for Proinnovera.

What industry is Proinnovera in?

Proinnovera's product category is Contract Research Organization (CRO) Services. Its primary akta.pro industry code is HLAGAAAL, Specialty Therapeutic-Area CROs (e.g., oncology/rare disease), with a secondary code of HLAGAAAA, Clinical CROs (Phase I–IV). Its NAICS code is 541714.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales